A Comparison of the Effects of Oxypertine and Trifluoperazine in Withdrawn Schizophrenics
- 1 December 1967
- journal article
- research article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 113 (505), 1419-1424
- https://doi.org/10.1192/bjp.113.505.1419
Abstract
There is a growing body of evidence that oxypertine (Win. 18,501), a recently developed indolylalkyl-phenyl-piperazine (1, 9), is of value in the treatment of schizophrenia (6). Oxypertine has been described as superior to trifluoperazine in its effect on certain aspects of schizophrenic behaviour (2, 5).This publication has 6 references indexed in Scilit:
- An Extended Trial of Oxypertine in Five Selected Cases of Chronic SchizophreniaThe British Journal of Psychiatry, 1967
- A Review of Clinical ExperienceThe British Journal of Psychiatry, 1965
- A Comparative Study of Oxypertine and Trifluoperazine in Chronic Schizophrenia—A New Application of the Wing Rating ScaleThe British Journal of Psychiatry, 1964
- Structure-Activity Relationships of 1-[3-Indolyl)alkyl]-4-arylpiperazines. A New Series of TranquilizersJournal of Medicinal Chemistry, 1962
- 1-(Indolylalkyl)-4-Arylpiperazines: A New Class of TranquilizersJournal of the American Chemical Society, 1962
- A Short Scale for Rating “Activity-Withdrawal” in SchizophrenicsJournal of Mental Science, 1957